Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Opus Genetics announces presentations of three Phase 3 clinical trial data on its phentolamine ophthalmic solution at the 2026 ASCRS Annual Meeting, including full results from VEGA-3 for presbyopia, a post-hoc analysis of MIRA-2 for mydriasis reversal, and LYNX-2 for visual disturbances post-refractive surgery. The company highlights collaboration…